Overview

Phase I Clinical Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of LYN101

Status:
ENROLLING_BY_INVITATION
Trial end date:
2027-09-06
Target enrollment:
Participant gender:
Summary
This is a Phase 1, two-part, first-in-human, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of LYN101 in healthy subjects (part A) and multiple doses in postmenopausal women with low bone mass (part B).
Phase:
PHASE1
Details
Lead Sponsor:
Shanghai TTM-Bio Technology Co., Ltd